Glaukos announced that the Current Procedural Terminology (CPT) Editorial Panel of the American Medical Association has granted 5-year extensions to three Category III CPT codes that describe insertion of aqueous drainage devices into the anterior chamber of the eye using microinvasive glaucoma surgery (MIGS).
CPT codes are used by physicians and other health care providers to report and receive Medicare reimbursement for healthcare services. In consultation with and with the support of the American Academy of Ophthalmology, American Glaucoma Society, and American Society of Cataract and Refractive Surgery, Glaukos requested and received extensions through December 31, 2023 on the following Category III CPT codes:
- 0191T, which describes insertion of an initial anterior segment aqueous drainage device such as the company’s iStent® Trabecular Micro-Bypass Stent and iStent inject® Trabecular Micro-Bypass Stent into the trabecular meshwork. The iStent was approved by the US Food & Drug Administration (FDA) and launched in 2012. The iStent inject is currently being evaluated in US clinical trials and has not been approved by the FDA.
- 0253T, which describes insertion of an anterior segment aqueous drainage device such as the company’s iStent SUPRA Suprachoroidal Micro-Bypass Stent into the suprachoroidal space. The iStent SUPRA is currently being evaluated in US clinical trials and has not been approved by the FDA.
- 0376T, which is an add-on code that describes insertion of additional anterior segment aqueous drainage devices, as with the iStent inject.
“The AMA CPT Editorial Panel’s decision to grant these extensions is important to the continued surgeon adoption of iStent and MIGS, a new technology class we pioneered to provide glaucoma patients a viable potential alternative to daily, multi-dose prescription eye drops or complex surgeries,” said Thomas Burns, Glaukos president and chief executive officer. “As we pursue FDA approval of our next-generation iStent technologies, we are pleased to have the corresponding CPT codes already in place and will use this time to continue to build upon the growing body of published research that documents their clinical performance.”
The iStent, which is the industry’s flagship MIGS device, is inserted through the trabecular meshwork and into Schlemm’s canal via a small corneal incision made during cataract surgery. Once in place, it is designed to restore the natural, physiological outflow of aqueous fluid and reduce intraocular pressure (IOP). The company is also pursuing FDA approval of two versions of its next-generation iStent inject device: one for use in combination with cataract surgery and another for use in a standalone procedure. The iStent inject is designed to deploy two stents into separate trabecular meshwork locations and is being evaluated for IOP reduction. The company is also pursuing FDA approval of a third MIGS device, the iStent SUPRA, which accesses a secondary pathway for aqueous humor outflow.